Literature DB >> 8805653

Mucosal or targeted lymph node immunization of macaques with a particulate SIVp27 protein elicits virus-specific CTL in the genito-rectal mucosa and draining lymph nodes.

L S Klavinskis1, L A Bergmeier, L Gao, E Mitchell, R G Ward, G Layton, R Brookes, N J Meyers, T Lehner.   

Abstract

The major routes of HIV transmission are through the rectal and cervico-vaginal mucosa. To prevent dissemination of HIV to the regional lymph nodes (LNs), an effective vaccine may need to stimulate CTL in the rectal or genital tract and the draining LNs. We report that mucosal immunization by the recto-oral and vagino-oral route or s.c. immunization targeting the iliac LNs with a particulate SIVp27:Ty-VLP vaccine elicits SIVgag-specific CTL in the regional LNs as well as in the spleen and PBMC. Targeted LN immunization with this vaccine elicited MHC class I-restricted CD8+ CTL responses, and the highest frequency of CTL was found in the iliac LNs. Moreover, SIVgag-specific CTL activity was detected in short term T cell lines established in mononuclear cells eluted from the rectal and cervico-vaginal mucosa. The relative frequency of CTL in short term cell lines prepared from the rectal mucosa (21/113 or 18.6%) was similar to that obtained from the cervico-vaginal mucosa (16/79 or 20.3%). Examination of the relative frequency of CTL to the T cell epitopes residing within SIVp27 showed a higher frequency in iliac LN cells to peptide aa 41-70 than in that to peptide aa 121-150, and this was significant after both recto-oral (chi-squared 6.500, p < 0.02) and vagino-oral (chi-squared = 10.391, p < 0.01) immunization. In contrast, the relative frequency of CTL in PBMC to peptide aa 41-70 (15.5%) was comparable to that elicited by peptide aa 121-150 (17.6%). This study provides novel evidence that mucosal or targeted LN immunization can generate anti-SIV CTL in the rectal and genital mucosa, in the draining LNs, and in the central lymphoid system.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8805653

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  Virus-like particles as vaccine adjuvants.

Authors:  S C Gilbert
Journal:  Mol Biotechnol       Date:  2001-10       Impact factor: 2.695

Review 2.  Recent advances in vaccine adjuvants.

Authors:  Manmohan Singh; Derek T O'Hagan
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

Review 3.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

4.  DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory.

Authors:  Mariana Manrique; Ewa Micewicz; Pamela A Kozlowski; Shainn-Wei Wang; Deepti Aurora; Robert L Wilson; Musie Ghebremichael; Gail Mazzara; David Montefiori; Angela Carville; Keith G Mansfield; Anna Aldovini
Journal:  AIDS Res Hum Retroviruses       Date:  2008-03       Impact factor: 2.205

5.  Oral immunization with recombinant Mycobacterium bovis BCG simian immunodeficiency virus nef induces local and systemic cytotoxic T-lymphocyte responses in mice.

Authors:  M Lagranderie; A M Balazuc; B Gicquel; M Gheorghiu
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

6.  Highly active antiretroviral therapy potently suppresses HIV infection in humanized Rag2-/-gammac-/- mice.

Authors:  Kaori Sango; Aviva Joseph; Mahesh Patel; Kristin Osiecki; Monica Dutta; Harris Goldstein
Journal:  AIDS Res Hum Retroviruses       Date:  2010-07       Impact factor: 2.205

7.  Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes.

Authors:  S Sasaki; K Sumino; K Hamajima; J Fukushima; N Ishii; S Kawamoto; H Mohri; C R Kensil; K Okuda
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

8.  Cervicovaginal lamina propria lymphocytes: phenotypic characterization and their importance in cytotoxic T-lymphocyte responses to simian immunodeficiency virus SIVmac251.

Authors:  Liljana Stevceva; Brian Kelsall; Janos Nacsa; Marcin Moniuszko; Zdenek Hel; Elzbieta Tryniszewska; Genoveffa Franchini
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

9.  Induction of human immunodeficiency virus type 1-specific T cells by a bluetongue virus tubule-vectored vaccine prime-recombinant modified virus Ankara boost regimen.

Authors:  Natasha Larke; Aileen Murphy; Christoph Wirblich; Denise Teoh; Marie J Estcourt; Andrew J McMichael; Polly Roy; Tomás Hanke
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

Review 10.  New routes for allergen immunotherapy.

Authors:  Pål Johansen; Seraina von Moos; Deepa Mohanan; Thomas M Kündig; Gabriela Senti
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.